DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,504 filers reported holding DANAHER CORPORATION in Q4 2019. The put-call ratio across all filers is 1.66 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,897,168 | +2.0% | 180,964 | -1.3% | 0.59% | +10.5% |
| Q2 2023 | $44,002,080 | -4.7% | 183,342 | +0.1% | 0.54% | -4.6% |
| Q1 2023 | $46,184,314 | +1.0% | 183,242 | +6.4% | 0.56% | +0.9% |
| Q4 2022 | $45,716,472 | +7.1% | 172,242 | +4.2% | 0.56% | +3.5% |
| Q3 2022 | $42,680,000 | +2395.9% | 165,242 | +2349.1% | 0.54% | +2457.1% |
| Q2 2022 | $1,710,000 | -13.6% | 6,747 | 0.0% | 0.02% | -8.7% |
| Q1 2022 | $1,979,000 | -10.6% | 6,747 | +0.3% | 0.02% | -11.5% |
| Q4 2021 | $2,213,000 | +8.7% | 6,727 | +0.6% | 0.03% | -3.7% |
| Q3 2021 | $2,035,000 | +11.0% | 6,686 | -2.2% | 0.03% | +12.5% |
| Q2 2021 | $1,834,000 | +9.6% | 6,835 | -8.1% | 0.02% | +4.3% |
| Q1 2021 | $1,673,000 | +1.3% | 7,435 | 0.0% | 0.02% | -4.2% |
| Q4 2020 | $1,652,000 | +3.2% | 7,435 | 0.0% | 0.02% | -4.0% |
| Q3 2020 | $1,601,000 | +23.4% | 7,435 | +1.4% | 0.02% | +25.0% |
| Q2 2020 | $1,297,000 | +27.8% | 7,335 | 0.0% | 0.02% | +11.1% |
| Q1 2020 | $1,015,000 | -6.9% | 7,335 | +3.2% | 0.02% | +28.6% |
| Q4 2019 | $1,090,000 | +8.5% | 7,105 | +2.2% | 0.01% | 0.0% |
| Q3 2019 | $1,005,000 | +1.1% | 6,955 | 0.0% | 0.01% | 0.0% |
| Q2 2019 | $994,000 | +8.3% | 6,955 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $918,000 | +38.7% | 6,955 | +8.4% | 0.01% | +27.3% |
| Q4 2018 | $662,000 | -5.0% | 6,415 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $697,000 | +8.6% | 6,415 | -1.4% | 0.01% | +10.0% |
| Q2 2018 | $642,000 | +0.8% | 6,505 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $637,000 | +2.6% | 6,505 | -2.7% | 0.01% | +11.1% |
| Q4 2017 | $621,000 | +5.6% | 6,685 | -2.5% | 0.01% | +12.5% |
| Q3 2017 | $588,000 | +1.7% | 6,855 | +0.1% | 0.01% | 0.0% |
| Q2 2017 | $578,000 | -7.2% | 6,845 | -6.0% | 0.01% | -11.1% |
| Q1 2017 | $623,000 | +7.2% | 7,285 | -2.4% | 0.01% | +12.5% |
| Q4 2016 | $581,000 | -3.0% | 7,465 | -2.4% | 0.01% | 0.0% |
| Q3 2016 | $599,000 | -24.2% | 7,645 | -2.3% | 0.01% | -33.3% |
| Q2 2016 | $790,000 | – | 7,825 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |